Kindly MD | 10-Q: FY2024 Q2 Revenue: USD 639.06 K

LB filings
2025.06.04 09:07

Revenue: As of FY2024 Q2, the actual value is USD 639.06 K.

EPS: As of FY2024 Q2, the actual value is USD -0.26.

EBIT: As of FY2024 Q2, the actual value is USD -1.037 M.

Segment Revenue

  • Patient Care Services: Revenue for the three months ended June 30, 2024, was $608,925, a decrease from $891,350 in the same period in 2023. For the six months ended June 30, 2024, revenue was $1,394,768, down from $1,959,305 in 2023.
  • Product Retail Sales: Revenue for the three months ended June 30, 2024, was $30,132, a decrease from $88,188 in the same period in 2023. For the six months ended June 30, 2024, revenue was $73,318, down from $180,578 in 2023.

Operational Metrics

  • Net Loss: For the three months ended June 30, 2024, the net loss was - $1,319,653, compared to - $596,408 for the same period in 2023. For the six months ended June 30, 2024, the net loss was - $1,601,979, compared to - $777,387 in 2023.
  • Operating Expenses: Total operating expenses for the three months ended June 30, 2024, were $1,676,250, an increase from $1,580,827 in 2023. For the six months ended June 30, 2024, operating expenses were $2,742,406, a decrease from $2,946,377 in 2023.

Cash Flow

  • Operating Cash Flow: Net cash used in operating activities for the six months ended June 30, 2024, was - $1,126,976, compared to - $274,964 in 2023.
  • Free Cash Flow: Not explicitly stated, but net cash provided by financing activities was $5,352,664 for the six months ended June 30, 2024, compared to $213,091 in 2023.

Unique Metrics

  • Insurance Reimbursements: The company earned $91,553 in reimbursements from insurance payers during the three months ending June 30, 2024, a 163.7% increase over the $34,722 earned for the three months ending March 31, 2024.

Future Outlook and Strategy

  • Core Business Focus: The company plans to continue shifting towards insurance billing with commercial and governmental payers, including Medicare and Medicaid, to optimize revenue and improve margins.
  • Non-Core Business: No specific plans related to divestitures or emerging segments were mentioned in the report.
Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.